In the ever-evolving landscape of active trading, AI-driven robots have become key players, providing insights and executing trades with precision. In this article, we delve into the recent performance of AI trading bots, particularly those accessible at "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)," which demonstrated their prowess by generating a notable +5.10% gain while trading BNGO over the past week.
BNGO's RSI Indicator Signals Transition
One crucial aspect of BNGO's recent trading activity is the Relative Strength Index (RSI) oscillator, which moved out of the overbought zone on December 29, 2023. This shift suggests a potential reversal from an upward trend to a downward one. Tickeron's A.I.dvisor, in analyzing similar instances, found that in 19 out of 20 cases where the RSI moved out of the overbought zone, the stock experienced a subsequent decline. This statistical observation gives traders a 90% likelihood of a downward move, prompting considerations for selling the stock or exploring put options.
Earnings Snapshot and Market Capitalization
Examining the last earnings report on November 09 reveals a notable -100 cents earnings per share, missing the estimated -97 cents. With 1.74 million shares outstanding, BNGO's current market capitalization stands at 59.43 million. It's crucial to note that this performance places BNGO within the Medical Specialties Industry, where the average market capitalization is 6.46 billion. Comparatively, BNGO's market cap appears significantly smaller, highlighting its distinct position within the industry.
Market Cap Comparisons
The Medical Specialties Industry presents a diverse range of market capitalizations, from 27 million to a staggering 3.82 trillion. Noteworthy companies in this sector include MKYSF with the highest valuation at 3.82 trillion and FOGCF at the lower end with a valuation of 27 million. BNGO's market cap, situated at 59.43 million, positions it within the mid-range of this industry spectrum.
Price Movements in the Industry
Understanding the broader market trends in the Medical Specialties Industry is essential. On average, weekly price growth for these stocks remained at 0%, while monthly growth registered at 11%, and quarterly growth at -6%. Within this spectrum, TIPS stood out with an impressive 286% price growth, while NMRD experienced a significant fall at -63%.
Volume Insights
Volume dynamics play a crucial role in understanding market activity. Across the Medical Specialties Industry, the average weekly volume growth was 127%, with monthly growth at 55%, and quarterly growth at 161%. These figures underscore the dynamic nature of trading within this sector and suggest heightened investor interest and participation.
The recent performance of AI trading bots, particularly in handling BNGO amidst changing market conditions, underscores the importance of adapting to evolving trends.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BNGO advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Indicator exited the oversold zone, of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on BNGO as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on July 02, 2025. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BNGO entered a downward trend on July 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.597) is normal, around the industry mean (24.469). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.993) is also within normal values, averaging (42.883).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of technologies for analysis of large biological molecules
Industry MedicalSpecialties